High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study
Open Access
- 12 March 2020
- Vol. 7 (3), 13
- https://doi.org/10.3390/medicines7030013
Abstract
Background: Serum phosphate levels, which are associated with the progression of renal dysfunction in chronic kidney disease, in patients with autosomal dominant polycystic kidney disease (ADPKD) are lower than those in patients with other kidney diseases. However, their role in ADPKD remains unclear. This study aimed to determine whether serum phosphate levels could have an association with renal prognoses among patients with ADPKD. Methods: In total, 55 patients with PKD1 or PKD2 mutations but not undergoing dialysis were evaluated. Data regarding serum phosphate levels were collected, and Cox regression analyses were used to calculate hazard ratios (HRs) with renal replacement therapy as the endpoint. Results: The median (quartile 1; quartile 3) serum phosphate concentration was 3.4 (3.1; 3.9) mg/dL, and the estimated glomerular filtration rate (eGFR) was 39.5 (17.6; 65.7) mL/min/1.73 m2. The multivariate analysis that included age, PKD1 mutation, eGFR, urinary protein excretion, hyperuricemia, and serum phosphate determined that eGFR (HR, 0.82; 95% confidence interval (CI), 0.74–0.90; p < 0.0001) and serum phosphate (HR, 6.78; 95% CI, 1.94–34.02; p = 0.0021) were independently associated with renal replacement therapy. Conclusions: We found that serum phosphate levels were significantly associated with poor renal prognoses in patients with ADPKD.Keywords
This publication has 25 references indexed in Scilit:
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- Soluble Klotho and Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE InhibitionJournal of the American Society of Nephrology, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Potentially Modifiable Factors Affecting the Progression of Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Serum phosphorus predicts incident chronic kidney disease and end-stage renal diseaseNephrology Dialysis Transplantation, 2011
- Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubuleThe FASEB Journal, 2010
- Unified Criteria for Ultrasonographic Diagnosis of ADPKDJournal of the American Society of Nephrology, 2009
- In vivo genetic evidence for klotho‐dependent, fibroblast growth factor 23 (Fgf23) ‐mediated regulation of systemic phosphate homeostasisThe FASEB Journal, 2008
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004